Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New data for Airsupra and Breztri highlight progress in advancing asthma and COPD care globally

Written by | 16 May 2025

AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in… read more.

Rocket Pharmaceuticals announces data from the Phase 1 clinical trial of RP A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy at ASGCT 2025

Written by | 15 May 2025

Rocket Pharmaceuticals a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced that the company will be… read more.

GSK to present 43 Abstracts at ATS 2025, highlighting advances in asthma, COPD and respiratory innovation

Written by | 14 May 2025

GSK plc announced data from across its respiratory portfolio will be presented in 43 abstracts, including four late-breaking submissions, at the 2025 American Thoracic Society (ATS) International Congress in… read more.

Sangamo to present 9 abstracts at ASGCT 2025, showcasing breakthroughs in neurology and gene regulation

Written by | 30 Apr 2025

Sangamo Therapeutics, Inc. , a genomic medicine company, announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the… read more.

Neurogene to share clinical insights on AAV9-linked HLH and Rett Syndrome Therapy at ASGCT 2025

Written by | 29 Apr 2025

Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation and participation in… read more.

Arbutus Biopharma to present 5 abstracts, including late-breaker, highlighting advancements in chronic hepatitis B treatment at EASL 2025

Written by | 28 Apr 2025

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association… read more.

Pfizer highlights progress in Oncology with over 60 presentations at ASCO 2025

Written by | 27 Apr 2025

Pfizer Inc will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30… read more.

Incyte announces multiple abstracts featuring new oncology data at ASCO 2025

Written by | 26 Apr 2025

Incyte announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago…. read more.

Atea Pharmaceuticals to showcase positive hepatitis C treatment results at EASL 2025

Written by | 25 Apr 2025

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, announced that the full results from the… read more.

Bayer and Vividion to unveil breakthroughs in targeted cancer therapies at AACR 2025

Written by | 24 Apr 2025

Bayer and Vividion Therapeutics, Inc. will present the latest research on their advancing oncology portfolio at the upcoming American Association for Cancer Research (AACR) 2025 Annual Meeting, taking place… read more.

United Therapeutics to highlight innovative pulmonary research at ATS 2025 conference in San Francisco

Written by | 23 Apr 2025

United Therapeutics Corporation  announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on… read more.

PDS Biotech to share new flu vaccine data at American Association of Immunologists’ IMMUNOLOGY2025 annual meeting

Written by | 18 Apr 2025

PDS Biotechnology Corporation, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.